TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02120118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
Study: NCT00464542

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: 500 mg, taken by mouth, two times a day, 7 days
Study: NCT02818738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Hydrochloride
Description: Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching verum
Study: NCT03176160

Intervention type: OTHER
Intervention: Palliative regimen consisting of LITT
Description: Minimally invasive technique to necrotize intracranial lesions
Study: NCT03936491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
Study: NCT03961594

Intervention type: OTHER
Group type: OTHER
Intervention: expansion volémique
Description: cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
Study: NCT02873923

Intervention type: DRUG
Intervention: undefined
Description: Chemotherapy drug (meta-analyses of randomized trials)
Study: NCT04092426

Intervention type: OTHER
Intervention: opthalmologic examination
Description: opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
Study: NCT04134663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasoconstrictor and oxytocin treatment
Description: intransal administration of vasoconstrictor and oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasoconstrictor's placebo and oxytocin treatment
Description: intransal administration of vasoconstrictor's placebo and oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vasoconstrictor and oxytocin's placebo treatment
Description: intransal administration of vasoconstrictor and oxytocin's placebo
Study: NCT04449588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: BDB-001 Injection+Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
Study: NCT03801018

Intervention type: OTHER
Intervention: Questionnary and Interviews
Description: An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation.

Intervention type: OTHER
Intervention: Questionnary and Interviews
Description: An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation.
Study: NCT02946502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handheld dynamometry (handgrip strength)
Description: Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
Study: NCT01444274

Intervention type: DEVICE
Intervention: Obalon Gastric Balloon(s)
Description: One or two balloons administered per patient
Study: NCT00857493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Study: NCT04295044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: receive 1.8g protein/kg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: receive 1g protein/kg
Study: NCT01638637

Intervention type: DEVICE
Intervention: APTIMA Assays; PANTHER System
Description: APTIMA Assays; PANTHER System
Study: NCT00561405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program
Description: Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
Study: NCT02777931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1
Description: NFC-1 is supplied as size 2 hard gelatin capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT03485131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
Study: NCT03368547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT00103259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT03451331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4.5 (based on the Calvert formula)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2
Study: NCT01680289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three adhesive coats
Description: After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two adhesive coats
Description: After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
Study: NCT00501696

Intervention type: DRUG
Group type: OTHER
Intervention: 4.5 mg Naltrexone
Description: low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)

Intervention type: DRUG
Group type: OTHER
Intervention: 4.5 mg Naltrexone
Description: low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: 4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
Study: NCT01092390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza (fish oil)
Description: 4 grams per day
Study: NCT01561586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weekly cisplatin with RT
Description: Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-weekly cisplatin with RT
Description: Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
Study: NCT01495169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone (oral tablet)
Description: iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
Study: NCT03958071

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib initiators

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone initiators

Intervention type: OTHER
Intervention: Untreated Cohort
Description: Untreated
Study: NCT03334526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental training
Description: The task to imagine for the training group will be an abduction of the thumb

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: electrical stimulation of the muscles
Study: NCT00574379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily for 14 days
Study: NCT00814619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo surgical resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study: NCT02687152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N-hydroxy-nor-L-arginine
Study: NCT01610700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each actuation of placebo delivered the excipients only.
Study: NCT01405391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Study: NCT02039817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Study: NCT03150134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: routine reduction of immunosuppressive drugs(cyclosporine)
Description: patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
Study: NCT01558869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 70 mg/m2 IV on day 1 of a 2-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 130 mg/m2 IV on day 1 of a 2-week cycle
Study: NCT02018159

Intervention type: DRUG
Intervention: menotropin
Study: NCT01318200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CyberKnife SBRT
Description: Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
Study: NCT04383080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture at specific acupuncture points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: low level laser emission on specific acupuncture points
Study: NCT00670267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadolol
Description: Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
Study: NCT02357407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients in intensive care : infection treated with ciprofloxacin IV
Description: 8-10 samples per patients on day-4 of their treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteoarticular infected patients : infection treated with oral ofloxacin
Description: 8-10 samples per patients on day-4 of their treatment
Study: NCT01766310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar tablet manufactured to mimic folic acid tablet
Study: NCT01523769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
Study: NCT00004161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo